CNBC·2026-01-30 20:44Core Insights - Upcoming Medicare coverage for obesity drugs is expected to significantly boost the rollout of Eli Lilly's experimental weight loss pill, orforglipron [1] - Eli Lilly anticipates Medicare coverage to begin immediately after the launch of orforglipron, which could alter the competitive landscape [1] - The early success of Novo Nordisk's GLP-1 obesity pill, Wegovy, indicates a strong market demand, with many early adopters being new to GLP-1 treatments [2] Company Strategy - Eli Lilly is preparing for a "full launch" of orforglipron in the second quarter, coinciding with the introduction of Medicare coverage for obesity medications [2] - The company is confident in its pill's competitive ability against existing treatments, particularly in light of the new Medicare coverage [2] Market Dynamics - The current market shows that many patients are paying out-of-pocket for Novo Nordisk's Wegovy, which has seen a strong start despite inconsistent insurance coverage [1] - The introduction of Medicare coverage for obesity drugs is part of drug pricing deals made with the Trump administration, which could further influence market dynamics [2]